News and Trends 25 May 2018 Norwegian Pancreatic Cancer Vaccine Drastically Improves Survival Targovax has obtained positive Phase I/II results showing its pancreatic cancer vaccine improved the survival of 32 patients also receiving chemotherapy over two years. Targovax, based in Oslo, Norway, has obtained positive Phase I/II results confirming the efficacy of its pancreatic cancer vaccine in a larger patient population and over a longer time period than […] May 25, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 24 May 2018 Sugar-Munching Microbes Put the ‘Eco’ into the Dyeing Industry The commercial dyeing industry is not known for being eco-friendly, which is something that PILI – a synbio startup based in France – is hoping to address with their color producing microbes. Philip chatted with its CEO, Jeremie Blache, to find out more about the company, its recent successful fundraising round and how its technology […] May 24, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2018 Organs-on-a-Chip for Drug Research in a Range of Diseases Make it to the Market CN Bio Innovations has globally launched an organ-on-a-chip device that allows scientists to test potential drugs on living human organ models. CN Bio Innovations, an Oxford University spin-out, has launched a device that enables scientists to test potential drugs in conventional cell culture labs without the need for animal models. The technology, which has been […] May 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 23 May 2018 Danish Biotech Raises Series A Round to Advance Microbe Engineering Technology Biosyntia has raised €4M in Series A financing from Sofinnova Partners to bring its microbe engineering technology closer to commercialization. Biosyntia, based in Copenhagen, has raised €4M in Series A financing to continue developing its biosynthetic selection technology to produce complex compounds by fermentation. The funding was provided by Sofinnova Partners, a new investor and leading European […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Another Pneumonia Antibiotic is Close to Treating Patients Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine. Roughly 30% of the population in Europe are allergic to grass pollen. The company plans […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Belgian Biotech Gets a €46M Boost to Keep up in the CAR-T Race Update (23/05/2018): Investors have fully subscribed Celyad’s global offering of shares on NASDAQ and Euronext Paris, making the company raise a total of $54.4M (€46M) to support the development of its CAR-T technology. 18/05/2018 Celyad has raised €40M ($47M) in a global offering, which could help the company keep up with large competitors amidst recent large […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2018 Celgene Partners With German Biotech to Develop Oncology Treatments Evotec has entered into a collaboration with Celgene to identify new therapeutics in oncology with a focus on solid tumors. Evotec, based in Hamburg, has received an upfront payment of $65M (€55M) from US-based Celgene, one of the largest biotechs worldwide. The funding will be used to identify potential new cancer treatments with a focus on […] May 22, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 22 May 2018 Poland’s Emerging Biotech Sector: The Time Is Right for Startups Poland might not be the first place you associate with biotech, but the country is becoming an emerging hotspot for pharmaceutical companies and biotech startups. Although Poland has a very strong scientific base in life sciences and medicine, it has not developed a vibrant biotech or medtech sectors. Until recently, no truly innovative products from […] May 22, 2018 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 21 May 2018 Engineering Red Blood Cells to Fight the Most Severe Cancers Our very own red blood cells could soon become a treatment for some of the most severe forms of cancer; After a long journey of ups and downs, Erytech is now near the finish line to launch the first red blood cell therapy. How amazing would it be if we could use our own cells […] May 21, 2018 - 6 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 18 May 2018 New Treatment for Rare Neurologic Eye Disease on Horizon from Spanish Biotech Spanish biotech Bionure has started an early stage trial of a new drug to treat rare neurologic eye diseases, which also shows promise for treatment of multiple sclerosis and other similar conditions. The therapy (BN201) is the first its class and if successful in clinical trials will be the only treatment that can help repair […] May 18, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Startup Scout 18 May 2018 This French Biotech Targets Retinal Cells to Treat Blindness Today, we’re in Paris, visiting SparingVision, a biotech trying to combat blindness using a protein that slows down the degeneration of cone cells in the retina. Mission: SparingVision uses a naturally occurring protein called rod-derived cone-viability factor, which binds to a transmembrane peptide on cone photoreceptor cells in the retina and allows more glucose to enter […] May 18, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email